We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-8.7%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.8B
AUM Growth
+$87.7M
Cap. Flow
+$861M
Cap. Flow %
17.92%
Top 10 Hldgs %
41.63%
Holding
117
New
20
Increased
33
Reduced
18
Closed
25

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$187M
2
ISRG icon
Intuitive Surgical
ISRG
+$94.9M
3
HUM icon
Humana
HUM
+$83.2M
4
BIIB icon
Biogen
BIIB
+$79.4M
5
UNH icon
UnitedHealth
UNH
+$65.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$123M
2
ARNA
Arena Pharmaceuticals Inc
ARNA
+$113M
3
LLY icon
Eli Lilly
LLY
+$95.2M
4
HOLX
Hologic
HOLX
+$81.5M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$79.1M

Sector Composition

Rank Sector Weight
1 Healthcare 91.22%
2 Financials 0.49%
3 Technology 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACET icon
26
Adicet Bio
ACET
$72.7M
$62.3M 1.3%
195,000
+5,375
+3% +$1.24M
KZR
27
DELISTED
Kezar Life Sciences
KZR
$58.5M 1.22%
351,800
+28,980
+9% +$4.16M
MCK icon
28
McKesson
MCK
$102B
$58M 1.21%
+189,500
New +$51.5M
ARGX icon
29
argenx
ARGX
$54.7B
$55.5M 1.16%
+176,000
New +$51.2M
BSX icon
30
Boston Scientific
BSX
$69.9B
$53M 1.1%
+1,196,100
New +$51.8M
NTRA icon
31
Natera
NTRA
$35.8B
$52.9M 1.1%
1,300,000
+360,000
+38% +$21.6M
EW icon
32
Edwards Lifesciences
EW
$48.5B
$51.8M 1.08%
+440,000
New +$49.4M
ARWR icon
33
Arrowhead Research
ARWR
$11.7B
$43.9M 0.91%
955,000
+80,000
+9% +$3.96M
IMCR icon
34
Immunocore
IMCR
$1.69B
$40.8M 0.85%
1,363,800
+133,800
+11% +$3.38M
LEGN icon
35
Legend Biotech
LEGN
$3.64B
$39.8M 0.83%
1,095,000
+383,100
+54% +$15.1M
XBI icon
36
State Street SPDR S&P Biotech ETF
XBI
$9.99B
$39.5M 0.82%
+440,000
New +$40.6M
BHC icon
37
Bausch Health
BHC
$1.7B
$38.7M 0.81%
+1,694,700
New +$41.4M
RNAM
38
DELISTED
Avidity Biosciences
RNAM
$37.8M 0.79%
2,045,000
+230,000
+13% +$3.91M
INSM icon
39
Insmed
INSM
$22.6B
$31.8M 0.66%
1,354,539
-95,461
-7% -$2.22M
ATEC icon
40
Alphatec Holdings
ATEC
$1.42B
$31.5M 0.66%
2,735,600
-37,400
-1% -$404K
IDYA icon
41
IDEAYA Biosciences
IDYA
$3.44B
$30.1M 0.63%
2,690,000
+137,000
+5% +$2.02M
CCXI
42
DELISTED
ChemoCentryx, Inc.
CCXI
$29.5M 0.61%
1,175,000
+530,600
+82% +$14.9M
AXSM icon
43
Axsome Therapeutics
AXSM
$12.2B
$29.4M 0.61%
711,000
-64,000
-8% -$1.98M
RCUS icon
44
Arcus Biosciences
RCUS
$3.33B
$28.8M 0.6%
+912,000
New +$30.6M
NTLA icon
45
Intellia Therapeutics
NTLA
$1.43B
$28.3M 0.59%
+390,075
New +$33M
PHAT icon
46
Phathom Pharmaceuticals
PHAT
$956M
$26.5M 0.55%
1,946,000
+50,000
+3% +$808K
CRBU icon
47
Caribou Biosciences
CRBU
$150M
$25.9M 0.54%
2,819,067
+145,000
+5% +$1.53M
NUVB icon
48
Nuvation Bio
NUVB
$2.29B
$25.5M 0.53%
4,855,006
-2,527,482
-34% -$14.2M
BLU
49
DELISTED
BELLUS Health Inc.
BLU
$25.4M 0.53%
3,685,000
-90,000
-2% -$580K
SPNE
50
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$24.4M 0.51%
2,010,000
– –
1
2
3 4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q1 2022 Portfolio in Review

As of Q1 2022, Avidity Partners Management held 117 positions worth $4.8B, up 1.9% from $4.71B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Avidity Partners Management deployed $861M of net new capital in Q1 2022, opening 20 new positions and adding to 33 existing holdings. Its largest new stake was Merck: 2,370,000 shares worth $194M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 98% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $79.1M trimmed.

  • Avidity Partners Management's largest Q1 2022 buy was Merck: 2,370,000 shares worth $194M.
  • Avidity Partners Management added most to UnitedHealth in Q1 2022, an estimated $65.8M increase.
  • Avidity Partners Management's biggest Q1 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $79.1M.
  • Avidity Partners Management fully exited Pfizer in Q1 2022, selling an estimated $123M.
  • Avidity Partners Management's ten largest holdings make up 42% of its $4.8B portfolio in Q1 2022.
  • Avidity Partners Management opened 20 new positions and closed 25 in Q1 2022.
  • Avidity Partners Management's portfolio value rose 1.9% quarter-over-quarter to $4.8B.

Based on Avidity Partners Management's 13F filing for Q1 2022, filed 16 May 2022.